Clinical Trial: A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN) (China)

China, Sept. 7 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN)'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131658

Registration Time: 2026/09/04

Type: Interventional study

Primary Sponsor: Zhejiang Cancer Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=265305

Published by HT Digital Content Services with permission from Health Daily Digest....